Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 07:00 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

We aim to leverage our public company platform to build a diversified digital asset portfolio while continuing to advance our innovative oncology pipeline.
October 22, 2025 14:26 ET | Source: BCC Research LLC

Molecular Diagnostics Market to Grow at 13.1% CAGR Through 2030

Boston, Oct. 22, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Molecular Diagnostics: Technologies and Global Markets” is projected to grow from $23 billion in 2025 to...
October 17, 2025 14:06 ET | Source: BCC Research LLC

Targeted Alpha Therapies Market to Grow at 44% CAGR Globally by 2030

Boston, Oct. 17, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Targeted Alpha Therapies for Cancer Treatment: Global Market” was valued at $199.6 million in 2024, and is...
October 15, 2025 17:45 ET | Source: Propanc Biopharma, Inc.

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

This accelerates development of our clinical pipeline and leverages Hexstone’s previous investments in companies that have built digital asset treasuries.
October 15, 2025 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

This accelerates development of our clinical pipeline and leverages Hexstone’s previous investments in companies that have built digital asset treasuries.
September 24, 2025 10:00 ET | Source: Medicovestor Inc

Medicovestor, Inc. Wins First Place at the Next Star North America Biomedical Special Competition in Boston, part of the 2025 Entrepreneur Next Star Million Prize Global Challenge

Medicovestor wins First Place at the 2025 Next Star Biomedical Competition in Boston for groundbreaking ADC platforms targeting pancreatic & ovarian cancer
September 17, 2025 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

A certificate of grant for Propanc’s “proenzyme composition” patent was received from the US Patent & Trademark Office.
September 16, 2025 13:00 ET | Source: UTR Therapeutics Inc.

UTR Therapeutics Publishes Landmark Preclinical Data in Frontiers in Pharmacology Supporting IND Submission for First-in-Class c-MYC RNA Therapeutic

UTR Therapeutics Inc Publishes Data supporting US FDA IND for a First-in-Human Clinical Trial of mRNA destabilizing drug targeting c-MYC driven cancer
September 03, 2025 16:07 ET | Source: Radiance BioPharma

Radiance Biopharma Signs Exclusive License For ‘First In Class’ c-Met/EGFR Targeted Nano Antibody ADC

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or "Company"), a clinical-stage biotechnology company, announced that it has signed an Exclusive License Agreement...
September 02, 2025 09:00 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Purchase of Ethereum will enhance a multi-faceted corporate strategy of cryptocurrency exposure, pharmaceutical drug development and asset acquisition.